HIF1A and hypertrophic cardiomyopathy: Thus, the deletion of HIF-1α reduces cardiomyocyte hypertrophy produced by HIMF and suppresses myocardial hypertrophy, making it a potential target for myocardial hypertrophy therapy.390 Reportedly, HIF-1α and PPAR are major regulators of glycolysis and lipid anabolism; the expression of these molecules is increased in hypertrophic cardiomyopathy.